Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507258 | 1.00 | TACR1 (0.59) | TACR1TSHRSLC6A2TAAR1MAOA | |
| SCHEMBL3553258 | 1.00 | TACR1 (0.59) | TACR1TSHRSLC6A2TAAR1MAOA | |
| Trifluoroacetic Acid SCHEMBL23390351 | 0.85 | SLC1A1 (0.51) | TACR1SLC6A2TAAR1MAOASLC6A4 | |
| Trifluoroacetic Acid SCHEMBL23390354 | 0.85 | SLC1A1 (0.51) | TACR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL7421010 | 0.84 | TACR1 (0.66) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL7332866 | 0.84 | TACR1 (0.66) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL9677926 | 0.84 | TACR1 (0.66) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL22013212 | 0.83 | TACR1 (0.63) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL7095981 | 0.83 | TACR1 (0.75) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL18394417 | 0.83 | TACR1 (0.63) | TACR1TSHRCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193636-A1 | Benzaldehyde reacted with a primary amine to give an imine, which is hydrogenated with hydrogen in the presence of a catalyst and a water miscible solvent | BASF AKTIENGESELLCHAFT (DE) | 2002-12-19 | — | — | US | claimed |
| US-6476268-B1 | Preparation of N-benzylamines | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | claimed |
| EP-1247799-A2 | Process for the preparation of N-benzylamines | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-09 | — | — | EP | claimed |
| CN-121779431-A | Synthesis method of key intermediate of ebastine | 山东盛安贝新材料有限公司 | 2026-04-03 | — | — | CN | disclosed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| US-20240294565-A1 | UNNATURAL CONFIGURATION NUCLEOTIDE PRODRUG COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED | 2024-09-05 | — | — | US | disclosed |
| CN-111527090-B | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230020092-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | ENTRADA THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| WO-2022245584-A1 | UNNATURAL CONFIGURATION NUCLEOTIDE PRODRUG COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-109863160-B | Nucleoside phosphate compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-2223929-A1 | GAMBOGIC GLYCOSIDE DERIVATIVES AND ANALOGS, THE PREPARATION AND THE APPLICATION THEREOF | Liaoning Lifeng Scientific&Technology Development Company Ltd. (CN) | 2010-09-01 | — | — | EP | disclosed |
| US-7288562-B2 | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-30 | — | — | US | disclosed |
| EP-1846469-A1 | A POLYUREA COMPOUND | Nuplex Resins B.V. (NL) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006075000-A1 | A POLYUREA COMPOUND | NUPLEX RESINS B.V. (NL) | 2006-07-20 | — | — | WO | disclosed |
| US-20020193636-A1 | Benzaldehyde reacted with a primary amine to give an imine, which is hydrogenated with hydrogen in the presence of a catalyst and a water miscible solvent | BASF AKTIENGESELLCHAFT (DE) | 2002-12-19 | — | — | US | disclosed |
| US-6476268-B1 | Preparation of N-benzylamines | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| EP-1247799-A2 | Process for the preparation of N-benzylamines | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-09 | — | — | EP | disclosed |
| EP-0877815-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE AMINES | BAYER AG (DE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997028271-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TACR1 801/4885TSHR 1878/4885SLC6A2 1378/4885 |
| US-20230020092-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | HNRNPAB, SNRPE, HNRNPA2B1 | TACR1 3300/4885TSHR 2244/4885SLC6A2 1820/4885 |
| US-20020193636-A1 | Benzaldehyde reacted with a primary amine to give an imine, which is hydrogenated with hydrogen in the presence of a catalyst and a water miscible solvent | HNMT, INMT, H1-2 | TACR1 3372/4885TSHR 3777/4885SLC6A2 1541/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | TACR1 801/4885TSHR 1878/4885SLC6A2 1378/4885 |
| US-20240294565-A1 | UNNATURAL CONFIGURATION NUCLEOTIDE PRODRUG COMPOUNDS | PNP, NUDT1, ENTPD5 | TACR1 1886/4885TSHR 3979/4885SLC6A2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.